121 related articles for article (PubMed ID: 19900495)
1. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs.
Chae SY; Jin CH; Shin JH; Son S; Kim TH; Lee S; Youn YS; Byun Y; Lee MS; Lee KC
J Control Release; 2010 Mar; 142(2):206-13. PubMed ID: 19900495
[TBL] [Abstract][Full Text] [Related]
2. Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives.
Son S; Chae SY; Kim CW; Choi YG; Jung SY; Lee S; Lee KC
J Med Chem; 2009 Nov; 52(21):6889-96. PubMed ID: 19827752
[TBL] [Abstract][Full Text] [Related]
3. The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics.
Chae SY; Choi YG; Son S; Jung SY; Lee DS; Lee KC
J Control Release; 2010 May; 144(1):10-6. PubMed ID: 20093159
[TBL] [Abstract][Full Text] [Related]
4. Biological activity of AC3174, a peptide analog of exendin-4.
Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
[TBL] [Abstract][Full Text] [Related]
5. Preparation and evaluation of palmitic acid-conjugated exendin-4 with delayed absorption and prolonged circulation for longer hypoglycemia.
Lee J; Lee C; Kim I; Moon HR; Kim TH; Oh KT; Lee ES; Lee KC; Youn YS
Int J Pharm; 2012 Mar; 424(1-2):50-7. PubMed ID: 22226877
[TBL] [Abstract][Full Text] [Related]
6. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
7. Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs.
Han J; Chen X; Zhao L; Fu J; Sun L; Zhang Y; Zhou F; Fei Y
Mol Pharm; 2018 Jul; 15(7):2840-2856. PubMed ID: 29799205
[TBL] [Abstract][Full Text] [Related]
8. Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics.
Kim TH; Jiang HH; Lee S; Youn YS; Park CW; Byun Y; Chen X; Lee KC
Bioconjug Chem; 2011 Apr; 22(4):625-32. PubMed ID: 21401109
[TBL] [Abstract][Full Text] [Related]
9. A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys.
Zhang L; Wang L; Meng Z; Gan H; Gu R; Wu Z; Gao L; Zhu X; Sun W; Li J; Zheng Y; Dou G
Biochem Biophys Res Commun; 2014 Mar; 445(2):511-6. PubMed ID: 24565847
[TBL] [Abstract][Full Text] [Related]
10. Long acting hyaluronate--exendin 4 conjugate for the treatment of type 2 diabetes.
Kong JH; Oh EJ; Chae SY; Lee KC; Hahn SK
Biomaterials; 2010 May; 31(14):4121-8. PubMed ID: 20149450
[TBL] [Abstract][Full Text] [Related]
11. Application of novel peptide (Pp1) improving the half-life of exendin-4 in vivo.
Zheng X; Li Y; Fu G; Gong M
Peptides; 2011 May; 32(5):964-70. PubMed ID: 21334413
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
[TBL] [Abstract][Full Text] [Related]
13. Site-specific PEGylated Exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects.
Kim TH; Jiang HH; Lim SM; Youn YS; Choi KY; Lee S; Chen X; Byun Y; Lee KC
Bioconjug Chem; 2012 Nov; 23(11):2214-20. PubMed ID: 23116483
[TBL] [Abstract][Full Text] [Related]
14. Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects.
Son S; Lim SM; Chae SY; Kim K; Park EJ; Lee KC; Na DH
Int J Pharm; 2015 Nov; 495(1):81-86. PubMed ID: 26325318
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle.
Arnés L; González N; Tornero-Esteban P; Sancho V; Acitores A; Valverde I; Delgado E; Villanueva-Peñacarrillo ML
Int J Mol Med; 2008 Jul; 22(1):127-32. PubMed ID: 18575785
[TBL] [Abstract][Full Text] [Related]
16. Identification of glycosylated exendin-4 analogue with prolonged blood glucose-lowering activity through glycosylation scanning substitution.
Ueda T; Ito T; Tomita K; Togame H; Fumoto M; Asakura K; Oshima T; Nishimura S; Hanasaki K
Bioorg Med Chem Lett; 2010 Aug; 20(15):4631-4. PubMed ID: 20576431
[TBL] [Abstract][Full Text] [Related]
17. Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes.
Kim H; Park H; Lee J; Kim TH; Lee ES; Oh KT; Lee KC; Youn YS
Biomaterials; 2011 Feb; 32(6):1685-93. PubMed ID: 21126761
[TBL] [Abstract][Full Text] [Related]
18. Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics.
Zhong X; Yang S; Liu T; Ji S; Hu J; Li H
Eur J Med Chem; 2018 Apr; 150():841-850. PubMed ID: 29597167
[TBL] [Abstract][Full Text] [Related]
19. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
[TBL] [Abstract][Full Text] [Related]
20. Exendin-4 and exercise promotes beta-cell function and mass through IRS2 induction in islets of diabetic rats.
Park S; Hong SM; Sung SR
Life Sci; 2008 Feb; 82(9-10):503-11. PubMed ID: 18237751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]